Enfortumab vedotin | m-entrepreneurship.com

Product Name :
Enfortumab vedotin

Search keywords :
Enfortumab

drugId :
null

Target Vo:
Nectin-4

Target Vo Short Name :
NECTIN4

Moa_Name:
Tubulin polymerisation inhibitors

First Approval Country :
United States

First Approval Date Filter:
2019

Origin Company_Name :
Agensys Inc

Active Company_Name :
Astellas (China) Investment Co Ltd

Active Indication_Name:
Carcinoma, Transitional Cell

In Active Indication_Name:
Neoplasms

Termination Status :

China Termination Status :

Highest Status:
Approved

China Highest Status:
NDA/BLA

Antibodies are immunoglobulins secreted by effector lymphoid B cells into the bloodstream. Antibodies consist of two light peptide chains and two heavy peptide chains that are linked to each other by disulfide bonds to form a “Y” shaped structure. Both tips of the “Y” structure contain binding sites for a specific antigen. Antibodies are commonly used in medical research, pharmacological research, laboratory research, and health and epidemiological research. They play an important role in hot research areas such as targeted drug development, in vitro diagnostic assays, characterization of signaling pathways, detection of protein expression levels, and identification of candidate biomarkers.
Related websites: https://www.medchemexpress.com/antibodies.html
Popular product recommendations:
Farletuzumab ecteribulin Antibody-drug Conjugate/ADC Related
Penpulimab Autophagy
Chk1 Antibody (YA505): Chk1 Antibody (YA505) is a non-conjugated and Rabbit origined monoclonal antibody about 54 kDa, targeting to Chk1. It can be used for WB,ICC/IF,IHC-P,FC assays with tag free, in the background of Human, Mouse.

Author: Betaine hydrochloride

Related Posts